在FGFR2b+≥10%的患者中疗效更加显著，PFS HR=0.43，OS HR=0.52,ORR 56.5%vs36.5%。在东亚人群的亚组分析中观察到更好的生存获益：mPFS为12.9vs8.2个月（HR=-.50），mOS为24.7vs12.9个月（HR=0.56）。安全性方面，角膜相关的不良反应是试验组治疗中断的主要原因，III期研究引入了眼部润滑剂和眼睑清洁的预防方案，有望降低相关毒性（来源： Zev A. Wainberg等，Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial ， Gastric Cancer. ， Yoon-Koo Kang 等，Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. Gastric Cancer.）。